ArticleNature communications2025
Mrc1 (MMR, CD206) controls the blood proteome in reducing inflammation, age-associated organ dysfunction and mortality in sepsis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Polysaccharide-engineered mitochondria reprogram macrophages to resolve diabetic wound inflammation and promote repair.Bioactive materials · 2026Article
- Liver sinusoidal endothelial cells in liver diseases and hepatocellular carcinoma: molecular mechanisms, physiology, and therapies.Molecular biomedicine · 2026Review
- LRP1 Activation Promotes Metabolic Reprogramming and Mrc1 Expression to Attenuate LPS-Induced Cognitive Deficits: An Integrated Omics Analysis.CNS neuroscience & therapeutics · 2026Article
- Myeloid compartment reprogramming through nanoparticle-delivered resiquimod blocks paracrine growth support and activates phagocytosis to slow tumor progression in endogenous mouse medulloblastoma and diffuse midline glioma models.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Circulating blood proteins and enzymes are maintained within normal physiological and clinically relevant concentration ranges. Excursions from normality include diagnostic markers and causes of disease. Rapid and persistent changes in the levels and functions of circulating blood components can reflect the functions of multiple endocytic lectin receptors. The majority of non-albumin blood proteins are post-translationally modified with sialylated N-glycans bearing cryptic ligands of various endocytic lectin receptors. During time in circulation, these cryptic ligands are progressively unmasked thereby contributing to glycoprotein half-life and abundance. The relationships between distinct lectin receptors and their endogenous ligand repertoires are not easily established. Herein we apply a glycosidic linkage enrichment strategy to identify accumulating mannosylated plasma glycoproteins linked to the absence of the endocytic Mrc1 (MMR, CD206) mannose-binding lectin receptor. We find that Mrc1 controls the abundance of over two hundred circulating endogenous mannosylated proteins in healthy mice at steady state, including glycoproteins linked to inflammation, age-associated organ dysfunction, and elevated mortality in sepsis. Increased circulating Mrc1 levels previously ascribed to proteolysis during sepsis are proportional to mannosylated protein accumulation in the blood. Assignment of circulating mannosylated proteins to curated biological and pathogenic signaling pathways reveals significant overlap between Mrc1 dysfunction and human sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.